{"id":16794,"date":"2025-07-15T14:15:18","date_gmt":"2025-07-15T14:15:18","guid":{"rendered":"https:\/\/www.colorectalcancercanada.com\/?p=16794"},"modified":"2025-07-15T14:15:58","modified_gmt":"2025-07-15T14:15:58","slug":"nouveau-traitement-de-premiere-intention-prometteur-pour-le-cancer-colorectal-metastatique-avec-mutation-braf-v600e","status":"publish","type":"post","link":"https:\/\/www.colorectalcancercanada.com\/fr\/essais-cliniques\/nouveau-traitement-de-premiere-intention-prometteur-pour-le-cancer-colorectal-metastatique-avec-mutation-braf-v600e\/","title":{"rendered":"Nouveau traitement de premi\u00e8re intention prometteur pour le cancer colorectal m\u00e9tastatique avec mutation BRAF V600E"},"content":{"rendered":"<p><a href=\"https:\/\/ascopost.com\/issues\/june-25-2025\/updated-results-confirm-benefit-of-combination-regimen-in-braf-v600e-mutated-metastatic-colorectal-cancer\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">Les r\u00e9sultats actualis\u00e9s<\/span><\/a><span data-contrast=\"auto\"> de l&rsquo;essai international de phase III BREAKWATER montrent que les patients atteints d&rsquo;un cancer colorectal m\u00e9tastatique avec mutation BRAF V600E peuvent vivre significativement plus longtemps lorsqu&rsquo;ils sont trait\u00e9s par une association d&rsquo;encorafenib, de c\u00e9tuximab et de la chimioth\u00e9rapie mFOLFOX6, par rapport \u00e0 la norme de soins actuelle pour ce sous-groupe de patients, qui consiste en une chimioth\u00e9rapie avec ou sans b\u00e9vacizumab.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Principaux r\u00e9sultats :\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"5\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">Les patients ayant re\u00e7u l&rsquo;encorafenib + le c\u00e9tuximab + la chimioth\u00e9rapie mFOLFOX6 ont pr\u00e9sent\u00e9 une survie globale m\u00e9diane de 30,3 mois, contre 15,1 mois avec la chimioth\u00e9rapie standard (avec ou sans b\u00e9vacizumab).<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"5\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"2\" data-aria-level=\"1\"><span data-contrast=\"auto\">Le d\u00e9lai avant aggravation du cancer (survie sans progression) \u00e9tait \u00e9galement plus long : 12,8 mois contre 7,1 mois.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"5\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"3\" data-aria-level=\"1\"><span data-contrast=\"auto\">Les taux de r\u00e9ponse ont \u00e9t\u00e9 significativement plus \u00e9lev\u00e9s avec la nouvelle association : 65,7 % contre 37,4 % avec le traitement standard.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"5\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"4\" data-aria-level=\"1\"><span data-contrast=\"auto\">Les r\u00e9ponses ont \u00e9galement dur\u00e9 plus longtemps : davantage de patients ont continu\u00e9 \u00e0 b\u00e9n\u00e9ficier du traitement pendant au moins 6 et 12 mois.\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><span data-contrast=\"auto\">S\u00e9curit\u00e9 :\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">La combinaison a \u00e9t\u00e9 g\u00e9n\u00e9ralement bien tol\u00e9r\u00e9e, sans effets secondaires inattendus. Les effets ind\u00e9sirables les plus fr\u00e9quents \u00e9taient les naus\u00e9es, l&rsquo;an\u00e9mie et la diarrh\u00e9e. Des effets secondaires graves sont survenus chez environ 46 % des patients sous le nouveau traitement, ce qui est comparable au traitement standard, et la plupart des patients ont pu poursuivre le traitement sans n\u00e9cessiter de r\u00e9duction importante de la dose.\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Message \u00e0 retenir :\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Ces r\u00e9sultats actualis\u00e9s confirment que l&rsquo;encorafenib + c\u00e9tuximab + chimioth\u00e9rapie mFOLFOX6 offre une am\u00e9lioration substantielle de la survie et du contr\u00f4le de la maladie chez les patients atteints d&rsquo;un cancer colorectal m\u00e9tastatique avec mutation BRAF V600E. Sur la base des donn\u00e9es ant\u00e9rieures de cette \u00e9tude, la Food and Drug Administration (FDA) aux \u00c9tats-Unis a d\u00e9j\u00e0 accord\u00e9 une autorisation acc\u00e9l\u00e9r\u00e9e \u00e0 cette association en tant que traitement de premi\u00e8re intention pour cette population de patients. La combinaison th\u00e9rapeutique fait actuellement l&rsquo;objet d&rsquo;un examen en vue d&rsquo;un remboursement au Canada par l&rsquo;Agence canadienne des m\u00e9dicaments.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Les r\u00e9sultats actualis\u00e9s de l&rsquo;essai international de phase III BREAKWATER montrent que les patients atteints d&rsquo;un cancer colorectal m\u00e9tastatique avec mutation BRAF V600E peuvent vivre significativement plus longtemps lorsqu&rsquo;ils sont trait\u00e9s par une association d&rsquo;encorafenib, de c\u00e9tuximab et de la chimioth\u00e9rapie mFOLFOX6, par rapport \u00e0 la norme de soins actuelle <a href=\"https:\/\/www.colorectalcancercanada.com\/fr\/essais-cliniques\/nouveau-traitement-de-premiere-intention-prometteur-pour-le-cancer-colorectal-metastatique-avec-mutation-braf-v600e\/\">&#8230;<\/a><\/p>\n","protected":false},"author":5,"featured_media":16858,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[57,98],"tags":[],"class_list":["post-16794","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-essais-cliniques","category-research-updates-fr"],"_links":{"self":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts\/16794","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/comments?post=16794"}],"version-history":[{"count":0,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts\/16794\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/media\/16858"}],"wp:attachment":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/media?parent=16794"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/categories?post=16794"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/tags?post=16794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}